Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

Show other versions (1)
Bibliographic Details
Main Authors: Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus, Peter A. Kaufman
Format: Article
Language:English
Published: SAGE Publishing 2016-06-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:http://www.la-press.com/subgroup-analyses-from-a-phase-3-open-label-randomized-study-of-eribul-article-a5733

Similar Items

Similar Items